Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on SVG103 (paxalisib) evaluating safety, tolerability, and pharmacokinetics in focal cortical dysplasia type II, tuberous sclerosis comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Cortical Dysplasia
• Hemimegalencephaly
• Tuberous Sclerosis Complex

Drugs mentioned

• SVG103 (Paxalisib) (paxalisib)

Snippet

Sponsor: Sovargen | Conditions: Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING